Searched for
WHISTLEBLOWER DINESH THAKUR
Why whistleblowing works in USAUS President Barack Obama took on the task of “cleaning up Wall Street” to protect small investors. And so the Dodd-Frank Wall Street Refor...- We’ve a long way to go in protecting whistleblowers: Ex-director of research, Ranbaxy, Dinesh ThakurDinesh Thakur was awarded $47 million by a US court in 2013 after he took his former employer to court for unethical practices.
- Delhi High Court seeks government reply on unsafe drugs ban pleaThe three medicines -- buclizine, flupenthixol+melitracen and aceclofenac+drotavarine -- together had a market size of around Rs 67 crore f...
- Ranbaxy whistleblower petitions PMO to investigate ‘Illegal’ drug approvalsRegulators today lack the “appropriate tools” to penalise pharmaceutical companies for violating the law, he claimed. An email sent to the ...
- NPPA to look into diabetes drug price-fixing allegationsVildagliptin is a proprietary drug of Novartis sold under the brand Galvus and comes under a new class of anti-diabetic drugs known as DPP ...
- How drug whistle-blowers in India have to fight a long battleThe fight by whistle-blowers for drug quality in India has cost them their dignity, jobs, and left them in severe financial duress.
- Not aware of adverse findings about manufacturing units of Ranbaxy: Sun Pharma“Based on our understanding of the matter, there is no truth to the assertions you are making,” a Sun spokesperson said in an email to ET.
- Ranbaxy whistleblower Dinesh Thakur may join PIL in Supreme CourtSharma wants three manufacturing sites banned on the grounds that they allegedly supplied adulterated drugs from these facilities.
- Ranbaxy whistleblower Dinesh Thakur may set up patient advocacy groupThakur is considering plans to set up a patient advocacy group that will aim to increase transparency and accountability among drug makers ...
- Internal whistleblowers ensure Pharma companies stick to guidelines and rulesDeloitte, which interviewed 33 companies, found one of the triggers for regulators to look at non-compliance came from tipoff from whistleb...
- Number of Indians turning whistle-blowers in US on the riseThere has been a fourfold jump in the number of Indians reporting secret tips about misconduct and fraudulent practices to US regulators, a...
- India criticizes US whistleblower policy; says it may lead to policy abuse by sore staffIndia has called for a review of the US whistleblower policy as it feels generous incentives offered by USFDA may lead to policy abuse by s...
- Ranbaxy whistleblower shares his experiences with US lawmakers“My case against Ranbaxy and what happened with Heparin in China show unscrupulous actors in global supply chain take advantage of gaps in ...
- Indian drug regulator seen as corrupt: Roger Bate'There is a growing perception in the US that India’s drug regulator is unwilling to monitor the quality of drugs manufactured by the local...
- Ranbaxy whistleblower Dinesh Thakur wants strong policy to unearth fraudConsidering that some of the cases were very sensitive, a minimum guarantee from the govt for whistle-blower is a basic pre-requisite, Thak...
- Ranbaxy got USFDA nod with no or fraudulent data: Whistleblower Dinesh ThakurRanbaxy Labs used "fraudulent" data to get USFDA nod to sell its generic drugs, according to whistleblower Dinesh Thakur, who also accused ...
- Major developments at Ranbaxy over the past decadeA series of revelations by Dinesh Thakur indicates that how troubles at Ranbaxy Laboratories were because of the fraudulent practices.
- Meet Dinesh Thakur: Former Ranbaxy employee who blew whistle and pocketed Rs 244 croreDinesh Thakur, pocketed Rs 244 crore for blowing the whistle on the dubious manufacturing practices of the country's largest drug maker Ran...
- Framing of whistle-blower policy is not yet mandatory for India IncIn India, a whistle blower is governed by an internal policy where cases of wrong doing of any kind are brought to the notice of the manage...
- Ranbaxy's top bosses wanted to destroy proof: Dinesh ThakurThakur, a former director of research information at Ranbaxy, has claimed that senior company executives ordered destruction of evidence.
Load More
